We found that animals receiving the two CHOP doses (CHOP×2 group) have higher numbers of CD4+ and CD8+ T cells recruited to the tumor as well as a significant increase in Il12 and Ifng and a decrease in Tgfb gene expression reinforcing the idea that CHOP treatment may indeed stimulate the development of effective antitumor immunity [30]. The gene discussed is DDIT3; the disease is neoplasm.